Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.48 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24722185 | 1.00 | GNAI3 (0.49) | GNAI3GNAO1GNAI1EPHX1RRM1 | |
| SCHEMBL27111043 | 0.98 | DPP7 (0.50) | GNAI3GNAO1GNAI1EPHX1RRM1 | |
| SCHEMBL20715708 | 0.93 | GNAI3 (0.46) | GNAI3GNAO1GNAI1EPHX1RRM1 | |
| SCHEMBL6015326 | 0.87 | FFAR4 (0.53) | GNAI3GNAO1GNAI1EPHX1RRM1 | |
| SCHEMBL11794051 | 0.85 | EPHX2 (0.50) | GNAI3GNAO1GNAI1EPHX1RRM1 | |
| SCHEMBL24443524 | 0.84 | GRIK1 (0.54) | GNAI3GNAO1GNAI1EPHX1RRM1 | |
| SCHEMBL944724 | 0.84 | EPHX1 (0.67) | EPHX1RRM1DPP7CASP2ZDHHC20 | |
| SCHEMBL81152 | 0.84 | EPHX1 (0.67) | EPHX1RRM1DPP7CASP2ZDHHC20 | |
| SCHEMBL947042 | 0.84 | EPHX1 (0.67) | EPHX1RRM1DPP7CASP2ZDHHC20 | |
| SCHEMBL3789783 | 0.84 | EPHX1 (0.67) | EPHX1RRM1DPP7CASP2ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | GNAI3 852/4885GNAO1 500/4885GNAI1 687/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | GNAI3 859/4885GNAO1 501/4885GNAI1 706/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | GNAI3 852/4885GNAO1 500/4885GNAI1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.